The expanded indication moves Pepaxti from fourth-line treatment to third-line treatment and beyond for adult patients with multiple myeloma, while removing the requirement for patients to be refractory to three drug classes (triple-class refractory, TCR).
The European Commission's decision confirms the positive recommendation issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in September.
BREAKING